Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-20
2007-03-20
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S323000, C514S339000, C514S412000, C514S414000, C544S143000, C546S201000, C546S277100, C548S515000, C548S465000
Reexamination Certificate
active
11065509
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2003/0216325 (2003-11-01), Saksena et al.
patent: 2005/0197301 (2005-09-01), Njoroge et al.
patent: 2005/0222047 (2005-10-01), Chen et al.
patent: 0 381 216 (1995-12-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 98/14181 (1998-04-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08198 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 200208244 (2002-01-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 03/035060 (2003-05-01), None
patent: WO 03/062228 (2003-07-01), None
Lamar, Jason, et al., “Novel P4 truncated tripeptidyl . . . ”, Bioorganic & Medicinal Chemistry Letters. 14: 263-266 (2004).
PCT International Search Report dated Sep. 15, 2005 for corresponding PCT Application No. PCT/US2005/005772.
Berenguer, Marina, et al., “Hepatitis B and C . . . ,” Proceedings of the Association of American Physicians 110(2):98-112 (1998).
Dimasi, Nazzareno, et al., “Characterization of Engineered . . . ,” Journal of Virology 71(10):7461-69 (1997).
Elzouki, Abdul-Nasser, et al., “Serine protease inhibitors . . . ,” Journal of Hepatology 27:42-48 (1997).
Failla, Cristina Maria, et al., “Redesigning the substrate . . . ,” Folding & Design 1(1):35-42 (Jan. 10, 1996).
Han, Wei, et al., “alpha-Ketoamidas, alpha-Ketoesters . . . ,” Bioorganic & Medicinal Chemistry Letters 10:711-713 (2000).
Hoofnagle, Jay H., et al., “The Treatment of . . . ,” Drug Therapy 336(5):347-56 (1997).
Ingallinella, Paolo, et al., “Potent Peptide Inhibitors . . . ,” Biochemistry 37:8906-14 (1998).
Kolykhalov, Alexander A., et al., “Specificity of the Hepatitis . . . ,” Journal of Virology 68(11):7525-7533 (Nov. 1994).
Komoda, Yasumasa, et al., “Substrate Requirements of . . . ,” Journal of Virology 68(11):7351-7357 (Nov. 1994).
Landro, James A., et al., “Mechanistic Role of an . . . ,” Biochemistry 36:9340-48 (1997).
Llinas-Brunet, Montse, et al., “Peptide-Based Inhibitors . . . ,” Bioorganic & Medicinal Chemistry Letters 8:1713-1718 (1998).
Marchetti, Antonella, et al., “Synthesis of Two Novel . . . ,” Synlett S1:1000-1002 (1999).
Martin, F., et al., “Affinity selection of a . . . ,” Protein Engineering 10(5):607-14 (1997).
Martin, Franck, et al., “Design of Selective of Selective . . . ,” Biochemistry 37:11459-68 (1998).
Pizzi, Elisabetta, et al., “Molecular model of . . . ,” Proc. Natl. Acad. Sci. USA 91:888-892 (Feb. 1994).
BioWorld Today 9(217):4 (Nov. 10, 1998).
U.S. Appl. No. 10/052,386, filed Jan. 18, 2002.
Arasappan Ashok
Bennett Frank
Blackman Melissa L.
Bogen Stephane L.
Chen Kevin X.
Farquharson-Torres Serena
Grazier Nyeemah
Kalyanaraman Palaiyur S.
Schering Corporation
LandOfFree
Compounds as inhibitors of hepatitis C virus NS3 serine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as inhibitors of hepatitis C virus NS3 serine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as inhibitors of hepatitis C virus NS3 serine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761469